Thyroid cancer is the most common endocrine tumor, and its incidence is increasing worldwide. The fourth edition (2017) of the WHO Classification of Tumors of Endocrine Organs reclassified thyroid cancer as PTC, FTC, HCC, PDTC, MTC, ATC, MMFTC, squamous cell carcinoma, mucoepidermoid carcinoma and so on. Thyroid cancer is heterogeneous in genetic alterations.
BRAF mutations are more prevalent in PTC, RAS and TERT promoter mutations are prevalent in FTC and FVPTC, mitochondrial DNA mutations are high frequency in HCC, TP53, TERT promoter, PIK3CA, PTEN and EIFAX mutations are prevalent in ATC and PDTC, RET mutations are prevalent in MTC. BRAF mutations are beneficial for the diagnosis of PTC. Genetic alterations form subsets of thyroid cancers with distinct clinicopathological features, and thyroid cancer with genetic alterations follows an aggressive clinical course and poor prognosis. Currently, the presence of unique molecular alterations (such as MAPK alterations) drive decisions related to Novel targeted therapy for advanced, metastatic or RAI-refractory thyroid carcinoma. Therefore, the role of genetic alterations is important in the diagnosis, treatment and prognosis of thyroid cancer.
This Research Topic aims to:
1) provide some new methods of genetic testing and strategies to improve the accuracy of gene detection in thyroid tumors and acquire the frequency of various gene mutations (including rare gene mutations) in different types of thyroid cancers.
2) provide new insight into several facets of the genetic alterations to the diagnosis role in thyroid tumors, to prediction value of clinicopathological features, recurrence, and mortality in thyroid cancers, and to decision significance making for surgical method, resection scope, and targeted therapies in unresectable thyroid cancer.
The Research Topic on “The Role of Genetic Alterations in Thyroid Cancer” had the bullet points as below: 1) New methods of genetic testing and strategies in thyroid tumors, 2) The frequency of various genetic alterations in different types of thyroid cancers, 3) acquire reports of rare gene mutations in thyroid cancers. 4) the diagnosis role of genetic alterations in thyroid cancers, 5) the prediction value of genetic alterations to clinicopathological features, recurrence, and mortality in different thyroid cancers, 6) the decision significance of genetic alterations to treatment strategies in thyroid cancers, especially PDTC and ATC, 7) obtain gene landscape of special thyroid cancers, such as advanced variants of PTC, HCC, mucoepidermoid carcinoma, sclerosing mucoepidermoid carcinoma with eosinophilia and so on.
Thyroid cancer is the most common endocrine tumor, and its incidence is increasing worldwide. The fourth edition (2017) of the WHO Classification of Tumors of Endocrine Organs reclassified thyroid cancer as PTC, FTC, HCC, PDTC, MTC, ATC, MMFTC, squamous cell carcinoma, mucoepidermoid carcinoma and so on. Thyroid cancer is heterogeneous in genetic alterations.
BRAF mutations are more prevalent in PTC, RAS and TERT promoter mutations are prevalent in FTC and FVPTC, mitochondrial DNA mutations are high frequency in HCC, TP53, TERT promoter, PIK3CA, PTEN and EIFAX mutations are prevalent in ATC and PDTC, RET mutations are prevalent in MTC. BRAF mutations are beneficial for the diagnosis of PTC. Genetic alterations form subsets of thyroid cancers with distinct clinicopathological features, and thyroid cancer with genetic alterations follows an aggressive clinical course and poor prognosis. Currently, the presence of unique molecular alterations (such as MAPK alterations) drive decisions related to Novel targeted therapy for advanced, metastatic or RAI-refractory thyroid carcinoma. Therefore, the role of genetic alterations is important in the diagnosis, treatment and prognosis of thyroid cancer.
This Research Topic aims to:
1) provide some new methods of genetic testing and strategies to improve the accuracy of gene detection in thyroid tumors and acquire the frequency of various gene mutations (including rare gene mutations) in different types of thyroid cancers.
2) provide new insight into several facets of the genetic alterations to the diagnosis role in thyroid tumors, to prediction value of clinicopathological features, recurrence, and mortality in thyroid cancers, and to decision significance making for surgical method, resection scope, and targeted therapies in unresectable thyroid cancer.
The Research Topic on “The Role of Genetic Alterations in Thyroid Cancer” had the bullet points as below: 1) New methods of genetic testing and strategies in thyroid tumors, 2) The frequency of various genetic alterations in different types of thyroid cancers, 3) acquire reports of rare gene mutations in thyroid cancers. 4) the diagnosis role of genetic alterations in thyroid cancers, 5) the prediction value of genetic alterations to clinicopathological features, recurrence, and mortality in different thyroid cancers, 6) the decision significance of genetic alterations to treatment strategies in thyroid cancers, especially PDTC and ATC, 7) obtain gene landscape of special thyroid cancers, such as advanced variants of PTC, HCC, mucoepidermoid carcinoma, sclerosing mucoepidermoid carcinoma with eosinophilia and so on.
